Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma has announced a partnership with AstraZeneca Pharma India to help patients living with Hyperkalaemia (a condition marked by dangerously high potassium levels in the blood, common in chronic kidney disease and heart failure patients) in India. The collaboration is aimed at improving access to treatment for this condition in the Indian market. A formal press release was issued on November 17, 2025, and the exchange has been informed accordingly. This is a distribution/access partnership leveraging both companies' strengths in the Indian pharmaceutical space.
This partnership is a positive development for Sun Pharma, expanding its therapeutic reach in India through collaboration with a global major. It may strengthen Sun Pharma's presence in the cardiac/renal care segment and could support modest revenue contribution, though no immediate material financial impact is indicated.